[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100431392":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":28,"locations":37,"responsibleParty":102,"collaborators":10,"id":104,"slug":105,"hasResults":106,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":10,"eligibilityCriteria":110,"healthyVolunteers":106,"sex":111,"minAge":112,"maxAge":10,"enrollmentInfo":113,"targetDuration":10,"studyType":116,"phases":10,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Grupo Argentino de Tratamiento de la Leucemia Aguda","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adult APL in first line",null,"Patients \\>\u002F= 18 years old with recent diagnosis of acute promyelocytic leukemia who receive treatment with ATO\u002FATRA according to our local guidelines. HR patients will receive 2-3 additional doses of idarubicin.",[13],"Other: Evaluation of first line treatment with ATO\u002FATRA outcome",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Evaluation of first line treatment with ATO\u002FATRA outcome","Evaluation of first line treatment with ATO\u002FATRA outcome (o event free survival and overall survival and toxicity) in adult patients with APL.",[9],[20,23,26],{"name":21,"affiliation":5,"role":22},"María José Mela Osorio, Dr.","PRINCIPAL_INVESTIGATOR",{"name":24,"affiliation":5,"role":25},"Isolda Fernández, Dr.","STUDY_CHAIR",{"name":27,"affiliation":5,"role":22},"Federico Sackmann, Dr.",[29,33],{"name":27,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+5491149720765","fsackmann@fundaleu.org.ar",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"Paula Freigeiro","+5491140470052","gatla.ar@gmail.com",[38,54,68,80,92,98],{"facility":39,"status":40,"city":41,"state":42,"zip":10,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Hospital Italiano de La Plata","RECRUITING","La Plata","Buenos Aires","Argentina","AR",{"type":46,"coordinates":47},"Point",[48,49],-57.95442,-34.92126,{"lat":49,"lon":48},[52],{"name":53,"role":30,"phone":10,"phoneExt":10,"email":10},"Hernán Dick, Dr.",{"facility":55,"status":40,"city":56,"state":57,"zip":10,"country":43,"countryCode":44,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Instituto Privado de Hematologia y Hemoterapia","Paraná","Entre Ríos Province",{"type":46,"coordinates":59},[60,61],-60.52897,-31.73271,{"lat":61,"lon":60},[64,66],{"name":65,"role":30,"phone":10,"phoneExt":10,"email":10},"Pedro Negri Aranguren, Dr.",{"name":67,"role":22,"phone":10,"phoneExt":10,"email":10},"Florencia Negri Aranguren, Dr.",{"facility":69,"status":40,"city":70,"state":71,"zip":10,"country":43,"countryCode":44,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Hospital Escuela de Agudos Dr. Ramón Madariaga","Posadas","Misiones Province",{"type":46,"coordinates":73},[74,75],-55.92379,-27.39184,{"lat":75,"lon":74},[78],{"name":79,"role":30,"phone":10,"phoneExt":10,"email":10},"Diego Wolhein, Dr.",{"facility":81,"status":40,"city":82,"state":83,"zip":10,"country":43,"countryCode":44,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Hospital Descentralizado Dr. Guillermo Rawson","Rawson","San Juan Province",{"type":46,"coordinates":85},[86,87],-68.54211,-31.58189,{"lat":87,"lon":86},[90],{"name":91,"role":30,"phone":10,"phoneExt":10,"email":10},"María Celina Vanina, Dr.",{"facility":93,"status":40,"city":94,"state":10,"zip":10,"country":43,"countryCode":44,"cosmosGeoPoint":10,"geoPoint":10,"contacts":95},"CEMIC","CABA",[96],{"name":97,"role":30,"phone":10,"phoneExt":10,"email":10},"Nicolás Cazap, Dr.",{"facility":99,"status":40,"city":94,"state":10,"zip":10,"country":43,"countryCode":44,"cosmosGeoPoint":10,"geoPoint":10,"contacts":100},"FUNDALEU",[101],{"name":27,"role":30,"phone":10,"phoneExt":10,"email":10},{"type":103,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100431392","rwe-of-1st-line-treatment-with-atoatra-for-adult-apl-100431392",false,"NCT04897490","RWE of 1st Line Treatment With ATO\u002FATRA for Adult APL","Real World Evidence of First Line Treatment With Arsenic Trioxide Plus All Trans Retinoic Acid in Adult Patients With Acute Promyelocytic Leukemia","Inclusion Criteria:\n\n* Patients 18 years or older.\n* Signature of the form consent for participation in the study.\n* Diagnosis of APL (either primary or secondary) according to the criteria of the World Health Organization (WHO), without prior treatment.\n* Identification of the specific genetic alteration of APL by conventional karyotype, fluorescent in situ hybridization (FISH), reverse transcriptase polymerase chain reaction (RT-PCR or RQ-PCR). Identification of the transcript is recommended at the time of diagnosis isoforms: bcr1, bcr2, bcr3 essential to document the therapeutic response: Molecular remission\n\nExclusion Criteria:\n\n* Presence of other concomitant active malignant tumors that require simultaneous treatment.\n* Having received prior treatment for APL.\n* Electrocardiogram abnormalities:\n\n  1. Patients with a pre-existing diagnosis of Long QT Syndrome\n  2. Patients with a baseline QTc of\\> 450msec. The Bazett formula should be used to measure the corrected QT interval (QT interval in msec divided by the square root of the RR interval in msec).\n  3. Patients with a history or presence of significant ventricular or atrial tachyarrhythmia (Grade 3-4, CTCAE v5.2017).\n  4. Patients with right bundle branch block plus left anterior hemiblock. Bifascicular blocks are excluded.\n* ECOG score 4.\n* Stage III-IV heart failure.\n* Serum creatinine ≥ 2.5 mg \u002F dL (≥ 250 μmol \u002F L) unless due to APL.\n* Bilirubin ≥ 2.5 mg \u002F dL, alkaline phosphatase, GPT or GOT\\> 3 times the normal limit unless it is for APL.\n* Severe psychiatric illness.\n* Women who are pregnant or who have decided to continue breastfeeding.","ALL","18 Years",{"count":114,"type":115},50,"ESTIMATED","OBSERVATIONAL","This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of acute promyelocytic leukemia (APL) patients in the first line with arsenic trioxide and all trans retinoic acid (ATO\u002FATRA) based regimens in Argentina.",[119],"Promyelocytic Leukemia, Adult Acute",[121,122,123,124],"Acute Promyelocytic Leukemia","ATRA","ATO","IDA","2024-01-08",{"date":127,"type":128},"2024-01-09","ACTUAL",{"date":130,"type":128},"2021-03-01",{"date":132,"type":115},"2026-12",{"name":5,"class":6},6]